IMPORTANT NOTICE: AATB Standards are subject to revision at any time pursuant to the Association’s procedures. Such revisions may consist of the addition of a new Standard, the rescission of an existing Standard, and/or the partial amendment of a Standard. Notice of each such revision is given by AATB by posting on the Association’s website, and distributing via email, a “Bulletin” that announces those changes and their respective effective dates. Persons seeking to determine the current provisions of Standards should always review the Bulletins for any such announcement of revisions to Standards or may request a current and effective copy of the Standards by sending a request to the AATB mailbox: accreditation@aatb.org. Please contact AATB's headquarters office for any questions concerning Standards or revisions thereof.
Bulletin 20-14
Published on: August 12, 2020
On July 2, 2020, the FDA notified the American Association of Tissue Banks (AATB) about some updates for tissue banks regarding the COVID-19 pandemic published on the FDA website under the title: “Updated Information for Human Cell, Tissue, or Cellular or Tissue-based Produc
Bulletin 20-13
Published on: July 31, 2020
The Board of Governors acted on recommendation from the Standards Committee and approved changes to the 14th Edition (2016) of AATB's Standards for Tissue Banking (see below) on June 22, 2020.
Bulletin 20-12
Published on: July 21, 2020
Today, the FDA announced an update to its final guidance document to revise “section V of the November 2017 guidance to communicate that the Agency is extending the period of time during which FDA intends to exercise enforcement discretion regarding certain regulatory requirements for certain HCT/Ps; this time period will run through May 31, 2021, instead of November 30, 2020.”
Bulletin 20-11
Published on: April 23, 2020
The Panel on COVID-19 formed by the AATB Physicians Council has issued the following:
Bulletin 20-10
Published on: April 02, 2020
The AATB Physicians Council formed a standing Panel, hereto known as PC Subgroup, to provide on-going surveillance of the emerging SARS CoV-2/COVID 19 situation. This PC Subgroup has been and will continue to collect data in order to assess, in real-time, the recommendations for our members for donor evaluation with the objective to protect recipients and recovery personnel, to the extent possible.
